Literature DB >> 21745312

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.

Kazuhiko Hayashi1, Yoshiaki Katano, Takashi Honda, Masatoshi Ishigami, Akihiro Itoh, Yoshiki Hirooka, Tetsuya Ishikawa, Isao Nakano, Kentaro Yoshioka, Hidenori Toyoda, Takashi Kumada, Hidemi Goto.   

Abstract

BACKGROUND AND AIMS: Mutations in the core and NS5A region of hepatitis C virus (HCV) genotype 1b have been associated with response to interferon (IFN) therapy. Genome-wide association studies have revealed that the single-nucleotide polymorphism (SNP) of interleukin 28B (IL28B) contributes to IFN response. The aim of this study was to investigate whether the SNP of IL28B (rs8099917) and amino acid substitutions in the core and NS5A region affect the response to IFN therapy.
METHODS: A total of 299 patients (157 men, 142 women; mean age, 55.9 ± 10.3 years) infected with HCV genotype 1b were studied. The fibrosis stage was diagnosed as F0 (n=23), F1 (n=121), F2 (n=62), F3 (n=32) and F4 (n=7) by liver biopsy.
RESULTS: Of the 299 patients, 138 achieved sustained virological response (SVR). On univariate analysis, predictors of SVR were age <60 years, male gender, higher platelet count, lack of fibrosis, non-Q at core 70, mutant-type interferon sensitivity-determining region (ISDR) and IL28B genotype TT. The factors related to SVR on multivariate analysis were IL28B (P=0.0001), fibrosis (P=0.0111) and mutations in the core region70 (P=0.0267) and ISDR (P=0.0408). The best SVR was achieved in patients with non-Q70, mutant-type ISDR and T allele (74.5%), and the worst was achieved in patients with Q70, wild-type ISDR and G allele (8.1%).
CONCLUSIONS: The SNP of IL28B and mutations in the core region and NS5A are associated with IFN responsiveness. Both host and viral factors might be useful for predicting IFN response.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21745312     DOI: 10.1111/j.1478-3231.2011.02571.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

Review 1.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

2.  Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.

Authors:  María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino
Journal:  BMC Med       Date:  2013-01-08       Impact factor: 8.775

3.  Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.

Authors:  Zhifang Jia; Yanhua Ding; Suyan Tian; Junqi Niu; Jing Jiang
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

4.  The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C.

Authors:  Danesh Kadjbaf; Maryam Keshvari; Seyed Moayed Alavian; Ali Pouryasin; Bita Behnava; Shima Salimi; Leila Mehrnoush; Pegah Karimi Elizee; Heidar Sharafi
Journal:  Hepat Mon       Date:  2016-05-03       Impact factor: 0.660

5.  Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.

Authors:  Nobuhiro Aizawa; Hirayuki Enomoto; Tomoyuki Takashima; Yoshiyuki Sakai; Kazunari Iwata; Naoto Ikeda; Hironori Tanaka; Yoshinori Iwata; Masaki Saito; Hiroyasu Imanishi; Hiroko Iijima; Shuhei Nishiguchi
Journal:  J Gastroenterol       Date:  2013-09-25       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.